| 摘要 |
<p>Modified bradykinin-type peptides of formula (I) and pharmaceutically acceptable salts are new A-Arg-B-C-D-W-X-Y-Z-Arg (I) where A=H, D- or L-amino acid residue, dipeptide or polypeptide contg. D- or L-amino acid residues, or an acyl, aromatic urethane or alkyl-type N-terminal protecting gp.; B=D-or L-Pro, or D- or L-cyclic aliphatic or opt. substd. aromatic acid residue; C=D- or L-Pro, or D- or L-cyclic, aliphatic or opt. substd. aromatic amino acid residue; D=Gly or L-aliphatic or opt. substd. aromatic amino acid residue; W=opt. substd. L-Phe, or L-aliphatic or opt. substd. aromatic amino acid residue; X=L-Ser, Gly or D- or L-aliphatic or opt. substd. aromatic amino acid residue; Y=D-aliphatic or opt. substd. aromatic amino acid residue; and Z=opt. substd. L-Phe or L-aliphatic or opt. substd. aromatic amino acid residue.</p> |
